COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to
                    Attempt?

Papachristou, Stella; Penlioglou, Theano; Stoian, Anca Pantea; Παπάνας, Νικόλαος

doi:10.1055/a-1235-5617

Cited by 5 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COVID-19 pandemic has emerged as a significant threat to healthcare systems, and treatment algorithms have changed in general surgical clinics, as has been the case in other medical disciplines during the outbreak. Although comorbidities and advanced age are factors statistically associated with increased mortality, the existence of severe forms of COVID-19 in young adults and among medical staff has increased the psychological pressure of those treating patients suspected or infected with SARS-CoV-2 (1)(2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

“…The etiologic agent, SARS-Cov-2, is an RNA virus in the Coronavirus family, generally responsible for benign respiratory infections, except for the causative agents of the Middle East respiratory syndrome (MERS) in 2012 and severe acute respiratory syndrome (SARS) during the 2002-2003 outbreaks (3)(4)(5). Infection modalities confirmed by clinical trials are through droplets, aerosols, direct and indirect contact (6,7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute surgical abdomen during the COVID‑19 pandemic: Clinical and therapeutic challenges

et al. 2021

View full text Add to dashboard Cite

The present study investigated the effects of the COVID-19 pandemic on the clinical presentation and therapeutic management of acute surgical abdomen. A retrospective study of emergency hospitalizations with a diagnosis of acute surgical abdomen between April and July 2020 vs. a similar period in 2019 was performed. The observation sheets and the operating protocols were analyzed. Between April and July 2020, 50 cases of acute surgical abdomen were hospitalized and treated, compared to 43 cases in the same period last year. The main types of pathology in both groups included: Occlusions (60%, respectively 44.2% in 2019) and peritonitis (32%, respectively 41.8% in 2019). There was an increased rate of patients with colorectal cancers neglected therapeutically or uninvestigated, who presented during the pandemic period with emergencies for complications such as occlusion or tumor perforation (32 vs. 6.97%, P=0.0039). One case, with gastric perforation, was COVID-positive, with no pulmonary symptoms at admission. The number of postoperative infectious complications was lower during the pandemic (2 vs. 13.95%, P=0.0461). As the COVID-19 pandemic appears to be still far from ending, we should learn to adapt our surgical protocols to the new evidence.Oncological patients are a vulnerable group, who were neglected in the first months of the pandemic. SARS-Cov-2 infection may be a cause of abdominal pain and should be taken into account in different diagnoses of acute abdomen in surgical wards. Correct wearing of adequate personal protective equipment (PPE) and respecting strict rules of asepsis and antisepsis are required for preventing in-hospital transmission of infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Acute surgical abdomen during the COVID‑19 pandemic: Clinical and therapeutic challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

“…DM is considered as a lowgrade inflammation state, which may aggravate the inflammatory process caused by SARS-CoV-2 leading to poor prognosis [10]. In this context, antidiabetic agents with the potential to reduce inflammation, hypoxia, liver injury and excess cytokine release are being discussed [11,12].…”

mentioning

confidence: 99%

Diabetes Mellitus and Hypertension as Major Risk Factors of Mortality From Covid-19 Pneumonia

Petrakis

Panagopoulos

Papazoglou

et al. 2020

Exp Clin Endocrinol Diabetes

Self Cite

View full text Add to dashboard Cite

Hospitalised patients with confirmed COVID-19 pneumonia (n = 172) Patients who died due toCOVID-19 pneumonia (n = 31) Age, years (mean, SD) 61.1 ± 15.8 69.2 ± 13.8 Gender Male (n, %) 98 (57 %) 18 (58 %) Comorbidities (n, %) Hypertension 66 (38.4 %) 24 (77.4 %) Diabetes mellitus 36 (20.9 %) 22 (71 %) Coronary artery disease 18 (10.5 %) 11 (35.5 %) Dyslipidaemia 36 (20.9 %) 16 (51.6 %) Heart failure 21 (12.2 %) 5 (16.1 %) Chronic kidney disease 11 (6.4 %) 3 (9.7 %) 205This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

show abstract

“…Telemedicine can be used to initiate, monitor, and titrate insulin accordingly. Some guidance suggests that modifying glucose-lowering drugs may be beneficial (particularly reducing use of metformin and sodium/glucose cotransporter-2 [SGLT-2] inhibitors, to reduce the risk of acute metabolic decompensation, such as lactic acidosis and diabetic ketoacidosis, and increasing use of incretin-based therapies due to their overlapping mechanisms with SARS-CoV-2), but that insulin treatment should be continued under all scenarios [19,22,[32][33][34][35][36]. In Croatia, during the pandemic, guidance was updated so that patients with BMI > 30 kg/m 2 could be prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; previously only accessible to patients with BMI > 35 kg/m 2 ) and, for those with type 2 diabetes and established CV disease, GLP-1 RAs could be given if their BMI was > 28 kg/m 2 .…”

Section: Management Of Patients With Diabetes and Obesity During The Covid-19 Pandemicmentioning

confidence: 99%

Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa

Giorgino¹,

Bhana²,

Czupryniak³

et al. 2021

Diabetes Research and Clinical Practice

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has had a major effect on healthcare during 2020. Current evidence suggests that, while individuals with diabetes and obesity are no more prone to SARS-CoV-2 infection than those without, the risk of hospitalisation if someone has diabetes or obesity and then contracts COVID-19 is three times higher -and 4.5 times higher if they have diabetes and obesity. We assembled a panel of experts from South and East Europe, the Middle East, and Africa to discuss the challenges to management of diabetes and obesity during and post the COVID-19 pandemic. The experience and learnings of this panel cover a heterogeneous patient population, wide range of clinical settings, healthcare organisations, disease management strategies, and social factors. We discuss the importance of timely and effective disease management via telemedicine, providing reassurance and guidance for patients unable or unwilling to visit healthcare settings at this time. We

show abstract

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Cited by 5 publications

References 12 publications

Acute surgical abdomen during the COVID‑19 pandemic: Clinical and therapeutic challenges

Acute surgical abdomen during the COVID‑19 pandemic: Clinical and therapeutic challenges

Diabetes Mellitus and Hypertension as Major Risk Factors of Mortality From Covid-19 Pneumonia

Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa

Contact Info

Product

Resources

About